AstraZeneca Ends AZD9412 IFN-β Asthma Trial For Redesign, Relaunch

AstraZeneca is stopping a Phase IIa trial assessing in-licensed AZD9412's effect on asthma patients because fewer of them than expected had their condition worsen, making it difficult for the respiratory specialist to gauge the drug's efficiency. AstraZeneca will now re-design the endpoints and resume the study in 2017.

Inhalers

AstraZeneca PLC has decided to stop INEXAS, the Phase IIa trial to investigate the effects on asthma patients of the inhaled Interferon beta-1a compound AZD9412 in-licensed from Synairgen PLC, because a mid-way analysis showed too few participants reported severe exacerbations, the primary endpoint target, making conclusions difficult.

INEXAS was initiated in June 2015 to study if inhaled Interferon beta-1a is safe and tolerated, and can prevent or...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Respiratory

More from Therapeutic Category